Prof. Xiaojia Chen, Ph.D. in Biochemistry and Molecular Biology, Senior Research Fellow of National Engineering Research Center of Genetic Medicine,Vice chairman of cell therapy and transformation branch of Guangdong Health Care Association.

She has been long engaged in the research and development of proteins and peptides. The research and development of targeted small molecule compounds and active peptides were carried out based on the three established screening platforms, phage display peptide library screening platform, combinatorial chemical one-bead one-compound (OBOC) unnatural amino acid peptide library and computer simulation docking analysis system, as well as the established 3D cell model and zebrafish disease model for evaluation.  At the same time, the functions of the above selected active molecules in the microenvironment of disease occurrence or tissue regeneration were explored. In addition, biomaterials, drug delivery or integrated detection systems for molecular imaging diagnosis and treatment containing above-mentioned active molecular are currently under research with cooperation with domestic and overseas partners.

Prof. Chen participated in the development of the second national genetic engineering novel drug recombinant basic fibroblast growth factor (rbFGF). She has presided over and participated in many national provincial and ministerial level and enterprise research projects and won three provincial and ministerial awards as the main participant. In recent years, she has published dozens of papers, 2 PCT international patents, and more than ten authorized invention patents by China Intellectual Property Administration. Up to now, three patents have transferred and an authorized patent is licensed.

2024年：

1.       Peiguang Zhang#, Jieqiong Cao#, Xujing Liang#, Zijian Su, Bihui Zhang, Zhenyu，Wang, Junye Xie, Gengrui Chen, Xue Chen, Jinting Zhang, Yanxian Feng, Qin Xu,, Jianping Song, An Hong***, Xiaojia Chen**, Yibo Zhang*. Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing the Yap1/FOXM1 pathway dependent lipid synthesis, Acta Biochimica et Biophysica Sinica，in press

2023年：

1.       Yibo Zhang*, Liu He*, Yiqi Yang, Jieqiong Cao,Zijian Su, Bihui Zhang, Huiying Guo, ZhenyuWang, Peiguang Zhang, Junye Xie, Jieruo Li,Jinshao Ye, Zhengang Zha, Hengyi Yu, An Hong#, Xiaojia Chen#. Triclocarban Triggers Osteoarthritis Via DNMT1-mediated Epigenetic Modification and Suppressionof COL2A in Cartilage Tissues. Journal of Hazardous Materials2023，447:130747. 

2.        Jieqiong Ca#, Yibo Zhang#, Yiqi Yang†, Junye Xie, Zijian Su, Fu Li, Jingsheng Li, Bihui Zhang, Zhenyu Wang, Peiguang Zhang, Zhixin Li, Liu He, Hongwei Liu, Wenjie Zheng, Shuixing Zhang*, An Hong* and Xiaojia Chen* Turning gray selenium and sublimed sulfur into a nanocomposite to accelerate tissue regeneration by isothermal recrystallization. Journal of Nanobiotechnology, (2023) 21（1）:57 

3.        Zijian Su#, Yibo Zhang#, Jieqiong Cao#, Yuanmeng Sun, Yuling Cai, Bihui Zhang, Liu He, Zilei Zhang,Junye Xie, Qilin Meng, Lin Luo, Fu Li, Jingsheng Li, Jinting Zhang, Xiaojia Chen* and An Hong*. Hyaluronic acid‑FGF2‑derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.Journal of Nanobiotechnology, (2023) 21（1）:55 

4.        Qilin Meng#, Lin Luo#, Minghua Lei, Zhiqi Chen, Yuanmeng Sun, Xue Chen, Zhaodong Zhai, Yibo Zhang, Jieqiong Cao, Zijian Su, Fu Li, Jingsheng Li,An Hong*, and XiaojiaChen*. Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis. Pharmaceuticals , 2023, 16, 548.  

5.        Yiqi Yang†, Yibo Zhang†, Jieqiong Cao†, Zijian Su, Fu Li, Peiguang Zhang, Bihui Zhang, Rongzhan Liu, Linhao Zhang, Junye Xie, Jingsheng Li, Jinting Zhang, Xiaojia Chen* and An Hong*. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. Journal of Experimental & Clinical Cancer Research, 2023, 42:96  

6.        Fu Li#, Minghua Lei#, Junye Xie，Shujun Guo,  Weicai Li, Xiujuan Ren, Teng Wang, Songxiong Lin , Qiuling Xie#, and Xiaojia Chen#. Discovery and Characteristics of a Novel Antitumor Cyclopeptide Derived from Shark.Bioengineering. 2023, 10(6), 674. 

7.        Yiqi Yang#, Bihui Zhan#, Junye Xie, Jingsheng Li, Jia Liu, Rongzhan Liu,Linhao Zhang, Jinting Zhang, Zijian Su, Fu Li, Leisheng Zhang*, An Hong*, and Xiaojia Chen*. CH02 peptide promotes ex vivo expansion of umbilical cord blood-derived CD34+ hematopoietic stem/progenitor cells. Acta Biochim Biophys Sin 2023, 55(8):1-10  

8.        Junye Xie#, Fu Li#, Yuling Cai, Jinting Zhang, Yibo Zhang, Zhaodong Zhai, Zijian Su, Xue Chen, Minghua Lei, Rongzhan Liu, Weicai Li, Dianlong Kang, Xiaojia Chen *, An Hong*.SAIF suppresses the angiogenesis via blocking VEGF-VEGFR2-ERK signaling and facilitates tumor treatment. Heliyon，9（2023）：e18240  

2022年：A1（1）区1篇

l  Jieqiong Cao#, Yibo Zhang#, Peiguang Zhang, Zilei Zhang, Bihui Zhang, Yanxian Feng,Zhixin Li , Yiqi Yang, Qilin Meng, Liu He, Yulin Cai, Zhenyu Wang, Jie Li, Xue Chen,Hongwei Liu, An Hong *, Wenjie Zheng*, Xiaojia Chen*. Turning gray selenium into a nanoaccelerator of tissue regeneration by PEG modification，Bioactive Materials，2022，15：131-144 

2021年：（通讯3）

1.        Ying Zhao#, Qiang Wang#, Chen Xie, Yuling Cai, Xue Chen, Yuhui Hou, Liu He, Jianping Li, Min Yao, Shuangxi Chen, Wutian Wu, Xiaojia Chen*,An Hong* . Peptide ligands targeting FGF receptors promote recovery from dorsal root crush injury via AKT/mTOR signaling. Theranostics 2021; 11(20): 10125-10147.; doi:10.7150/thno.62525; 

2.        Yuan Jin*, Qilin Meng*, Bihui Zhang, Chen Xie, Xue Chen, Baoqing Tian, Jiakang，Wang, Tsung-Chieh Shih, Yibo Zhang, Jieqiong Cao, Yiqi Yang, Size Chen, Xinyuan，Guan, Xiaojia Chen#, An Hong#. Cancer-associated fibroblast-derived exosomal miR-3656 promotes the development and progression of esophageal squamous cell carcinoma via the ACAP2/PI3K-AKT signaling pathway. Int. J. Biol. Sci. 2021; 17(14): 3689-3701. doi: 10.7150/ijbs.62571 

3.        Wang, Y.*; Li, Y. *; Cao, J.*;Meng, Q.; Li, X.; Zhang, Y.; Lam, K.S.; Hong, A.; Liu, R.#; Chen, X#. Development and Characterization of a Novel Peptide Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors. Biomedicines 2021, 9(8): 849. doi.org/ 10.3390/biomedicines9080849 

4.        Jianxin Yan*, Jiaji Liang*, Yingxuan Cao, Mariya M. El Akkawi, Xuan Liao, Xiaojia Chen, Chengzhi Li, Kecheng Li, Guanghui Xie and Hongwei Liu#.  Efficacy of topical and systemic transplantation of mesenchymal stem cells in a rat model of diabetic ischemic wounds. Stem Cell Research & Therapy (2021) 12:220 doi.org/10.1186/s13287-021-02288-8

2020年（2篇，通讯2）

1.       Yibo Zhang*,Man Ouyang*, HailongWang, Bihui Zhang, Wenhua Guang,Ruiwu Liu2 Xiaocen Li2 Tsung-Chieh Shih, Zhixin Li, Jieqiong Cao, Qiling Meng,  Zijian Su,  Jinshao Ye, Feng Liu, An Hong#, Xiaojia Chen#.  A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2，MedComm. 2020;1:362–375.DOI: 10.1002/mco2.48  

2.       Qiang Wang , Ying Zhao , Xiaojia Chen# & An Hong#.Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2. Journal of Biomolecular Structure and Dynamics. 2022,40(1/2)： 685-695；  Published online: 10 Sep 2020, https://doi.org/10.1080/07391102.2020.1817786